Please use this identifier to cite or link to this item:
https://repositorio.ufba.br/handle/ri/12312
metadata.dc.type: | Artigo de Periódico Artigo de Periódico |
Title: | Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil: a randomized and controlled trial |
Other Titles: | PLoS Neglected Tropical Diseases |
Authors: | Machado, Paulo Roberto Lima Ampuero, Julia Guimarães, Luiz H. Villasboas, Leonardo Rocha, Ana T. Schriefer, Nicolaus Albert Borges Sousa, Rosana Santos Talhari, Anette Chrusciak Penna, Gerson de Oliveira Carvalho Filho, Edgar Marcelino de |
metadata.dc.creator: | Machado, Paulo Roberto Lima Ampuero, Julia Guimarães, Luiz H. Villasboas, Leonardo Rocha, Ana T. Schriefer, Nicolaus Albert Borges Sousa, Rosana Santos Talhari, Anette Chrusciak Penna, Gerson de Oliveira Carvalho Filho, Edgar Marcelino de |
Abstract: | Background: Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance. Methodology/Principal Findings: This study is a randomized, open-label, controlled clinical trial aimed to evaluate the efficacy and safety of miltefosine versus pentavalent antimony (Sbv) in the treatment of patients with CL caused by Leishmania braziliensis in Bahia, Brazil. A total of 90 patients were enrolled in the trial; 60 were assigned to receive miltefosine and 30 to receive Sbv. Six months after treatment, in the intention-to-treat analyses, the definitive cure rate was 53.3% in the Sbv group and 75% in the miltefosine group (difference of 21.7%, 95% CI 0.08% to 42.7%, p = 0.04). Miltefosine was more effective than Sbv in the age group of 13–65 years-old compared to 2–12 years-old group (78.9% versus 45% p = 0.02; 68.2% versus 70% p = 1.0, respectively). The incidence of adverse events was similar in the Sbv and miltefosine groups (76.7% vs. 78.3%). Vomiting (41.7%), nausea (40%), and abdominal pain (23.3%) were significantly more frequent in the miltefosine group while arthralgias (20.7%), mialgias (20.7%) and fever (23.3%) were significantly more frequent in the Sbv group. Conclusions: This study demonstrates that miltefosine therapy is more effective than standard Sbv and safe for the treatment of CL caused by Leishmania braziliensis in Bahia, Brazil. |
URI: | http://www.repositorio.ufba.br/ri/handle/ri/12312 |
Issue Date: | Dec-2010 |
Appears in Collections: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Paulo Machado.pdf | 344,17 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.